专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005069834A2 4-ARYL PIPERIDINES 审中-公开
公开(公告)号：WO2005069834A2
公开(公告)日：2005-08-04
申请号：PCT/US2005/001131
申请日：2005-01-13
申请人： H. LUNDBECK A/S , MARZABADI, Mohammad, R. , WETZEL, John, M. , CHEN, Chien-An , DELEON, John, E. , JIANG, Yu , LU, Kai
发明人： MARZABADI, Mohammad, R. , WETZEL, John, M. , CHEN, Chien-An , DELEON, John, E. , JIANG, Yu , LU, Kai
IPC分类号： C07D211/26
CPC分类号： C07D211/26
摘要： This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject’s depression and/or anxiety.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的4-芳基哌啶和相关的杂环化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物与药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用有效治疗受试者的抑郁症和/或焦虑的量的本发明化合物。

2. 发明申请

WO2006041636A2 AMINO SUBSTITUTED ARYLOXYBENZYLPIPERIDINE DERIVATIVES 审中-公开
标题翻译：氨基取代的芳氧基苯基哌啶衍生物
公开(公告)号：WO2006041636A2
公开(公告)日：2006-04-20
申请号：PCT/US2005033891
申请日：2005-09-20
申请人： LUNDBECK & CO AS H , MARZABADI MOHAMMAD R , CHEN CHIEN-AN , YU JIANG , LU KAI , ANDERSEN KIM
发明人： MARZABADI MOHAMMAD R , CHEN CHIEN-AN , YU JIANG , LU KAI , ANDERSEN KIM
IPC分类号： A61K31/5377 , A61K31/4545 , A61K31/496 , C07D313/14 , C07D403/14
CPC分类号： C07D211/26 , C07D401/12 , C07D403/12
摘要： This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/ or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.
摘要翻译：本发明涉及作为MCH1受体配体的氨基取代的芳氧基苄基哌啶衍生物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明还提供了通过混合治疗有效量的本发明化合物和药学上可接受的载体制成的药物组合物。本发明进一步提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。本发明还提供了治疗患有肥胖症的对象的方法，该方法包括给对象施用治疗有效量的本发明化合物。

3. 发明申请

WO2006041635A3 ARYLTHIOBENZYLPIPERIDINE DERIVATES 审中-公开
公开(公告)号：WO2006041635A3
公开(公告)日：2006-04-20
申请号：PCT/US2005/033870
申请日：2005-09-21
申请人： H. LUNDBECK A/S , MARZABADI, Mohammad, R. , JIANG, Yu , CHEN, Chien-An , LU, Kai , ANDERSEN, Kim
发明人： MARZABADI, Mohammad, R. , JIANG, Yu , CHEN, Chien-An , LU, Kai , ANDERSEN, Kim
IPC分类号： A61K31/5377 , A61K31/445 , C07D211/06 , C07D413/12
摘要： This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

4. 发明申请

WO2006041635A2 ARYLTHIOBENZYLPIPERIDINE DERIVATES 审中-公开
标题翻译：亚油酸苄酯衍生物
公开(公告)号：WO2006041635A2
公开(公告)日：2006-04-20
申请号：PCT/US2005033870
申请日：2005-09-21
申请人： LUNDBECK & CO AS H , MARZABADI MOHAMMAD R , JIANG YU , CHEN CHIEN-AN , LU KAI , ANDERSEN KIM
发明人： MARZABADI MOHAMMAD R , JIANG YU , CHEN CHIEN-AN , LU KAI , ANDERSEN KIM
IPC分类号： C07D413/14 , C07D401/14
CPC分类号： C07D211/60 , C07D211/26 , C07D401/04 , C07D401/12 , C07D401/14
摘要： This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.
摘要翻译：本发明涉及作为MCH1受体的配体的芳硫基苄基哌啶衍生物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。本发明还提供了治疗患有肥胖症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。

5. 发明申请

WO2005069834A3 4-ARYL PIPERIDINES 审中-公开
公开(公告)号：WO2005069834A3
公开(公告)日：2006-04-27
申请号：PCT/US2005001131
申请日：2005-01-13
申请人： LUNDBECK & CO AS H , MARZABADI MOHAMMAD R , WETZEL JOHN M , CHEN CHIEN-AN , DELEON JOHN E , JIANG YU , LU KAI
发明人： MARZABADI MOHAMMAD R , WETZEL JOHN M , CHEN CHIEN-AN , DELEON JOHN E , JIANG YU , LU KAI
IPC分类号： C07D211/26 , A61K31/445 , C07D211/68 , C07D401/04 , C07D401/10 , C07D401/14
CPC分类号： C07D211/26
摘要： This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的4-芳基哌啶和相关的杂环化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物与药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

6. 发明申请

WO2006041636A3 AMINO SUBSTITUTED ARYLOXYBENZYLPIPERIDINE DERIVATIVES 审中-公开
公开(公告)号：WO2006041636A3
公开(公告)日：2006-04-20
申请号：PCT/US2005/033891
申请日：2005-09-20
申请人： H.LUNDBECK A/S , MARZABADI, Mohammad, R. , CHEN, Chien-An , YU, Jiang , LU, Kai , ANDERSEN, Kim
发明人： MARZABADI, Mohammad, R. , CHEN, Chien-An , YU, Jiang , LU, Kai , ANDERSEN, Kim
IPC分类号： A61K31/4427 , C07D401/06
摘要： This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/ or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

7. 发明申请

WO2006041635A8 ARYLTHIOBENZYLPIPERIDINE DERIVATIVES 审中-公开
标题翻译：芳基硼烷衍生物衍生物
公开(公告)号：WO2006041635A8
公开(公告)日：2007-05-18
申请号：PCT/US2005033870
申请日：2005-09-21
申请人： LUNDBECK & CO AS H , MARZABADI MOHAMMAD R , JIANG YU , CHEN CHIEN-AN , LU KAI , ANDERSEN KIM
发明人： MARZABADI MOHAMMAD R , JIANG YU , CHEN CHIEN-AN , LU KAI , ANDERSEN KIM
IPC分类号： A61K31/5377 , A61K31/445 , C07D211/06 , C07D413/12
CPC分类号： C07D211/60 , C07D211/26 , C07D401/04 , C07D401/12 , C07D401/14
摘要： This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.
摘要翻译：本发明涉及作为MCH1受体的配体的芳硫基苄基哌啶衍生物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。本发明还提供了治疗患有肥胖症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。

8. 发明申请

WO2004064764A3 SUBSTITUTED ALKYL AMIDO PIPERIDINES 审中-公开
标题翻译：取代的烷基氨基哌啶
公开(公告)号：WO2004064764A3
公开(公告)日：2005-01-13
申请号：PCT/US2004000175
申请日：2004-01-06
申请人： SYNAPTIC PHARMA CORP , MARZABADI MOHAMMAD R , WETZEL JOHN M , CHEN CHIEN-AN , JIANG YU , LU KAI
发明人： MARZABADI MOHAMMAD R , WETZEL JOHN M , CHEN CHIEN-AN , JIANG YU , LU KAI
IPC分类号： A61K31/44 , A61K31/445 , A61K31/451 , A61K31/4523 , A61K31/4525 , A61K31/453 , A61K31/4535 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/497 , A61K31/506 , A61K31/53 , A61K31/5377 , A61P3/04 , A61P7/12 , A61P25/22 , A61P25/24 , A61P43/00 , C07D211/06 , C07D211/26 , C07D211/28 , C07D211/30 , C07D211/90 , C07D211/94 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04 , C07D521/00
CPC分类号： C07D211/26 , C07D211/28 , C07D211/90 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物与药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

9. 发明申请

WO2004064764A2 SUBSTITUTED ALKYL AMIDO PIPERIDINES 审中-公开
标题翻译：取代的烷基氨基哌啶
公开(公告)号：WO2004064764A2
公开(公告)日：2004-08-05
申请号：PCT/US2004/000175
申请日：2004-01-06
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION , MARZABADI, Mohammad, R. , WETZEL, John, M. , CHEN, Chien-An , JIANG, Yu , LU, Kai
发明人： MARZABADI, Mohammad, R. , WETZEL, John, M. , CHEN, Chien-An , JIANG, Yu , LU, Kai
IPC分类号： A61K
CPC分类号： C07D211/26 , C07D211/28 , C07D211/90 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物与药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

10. 发明申请

WO1996014846A1 DIHYDROPYRIMIDINES AND USES THEREOF 审中-公开
标题翻译：二氢嘧啶及其用途
公开(公告)号：WO1996014846A1
公开(公告)日：1996-05-23
申请号：PCT/US1995015025
申请日：1995-11-16
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION , NAGARATHNAM, Dhanapalan , CHIU, George , DHAR, T., G., Murali , WONG, Wai, C. , MARZABADI, Mohammad, R. , GLUCHOWSKI, Charles , LAGU, Bharat , MIAO, Shou Wu
发明人： SYNAPTIC PHARMACEUTICAL CORPORATION
IPC分类号： A61K31/50
CPC分类号： C07D239/30 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/14 , C07D491/04
摘要： This invention is directed to dihydropyrimidine compounds which are selective antagonists for human alpha 1C receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where the antagonism of the alpha 1C receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为人α1C受体的选择性拮抗剂的二氢嘧啶化合物。本发明还涉及这些化合物降低眼内压，抑制胆固醇合成，放松下尿路组织，治疗良性前列腺增生，阳ence，心律失常以及用于治疗其中α1C拮抗作用的任何疾病受体可能是有用的。本发明还提供了包含治疗有效量的上述化合物和药学上可接受的载体的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式